at Benzinga.com (Dec 30, 2014)
Dendreon (DNDN) yesterday confirmed that the SEC has opened an investigation, which could be connected to lawsuits accusing the company of misleading investors over Provenge. While Dendreon had initially been bullish about the prostate-cancer treatment, it shocked the market in August 2011 when it said that adoption was slow, causing Dendreon's stock to plunge over 65% in one day.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Nov 18, 2014)
at Zacks.com (Nov 11, 2014)
at CNBC.com (Nov 10, 2014)
at Zacks.com (Nov 10, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs